48 results about "Contragestazol" patented technology

A combination hormone and melatonin therapy is provided to reduce the risk of developing, or to reduce the severity of, breast cancer by administering at least one estrogen hormone and optionally at least one progesterone-receptor-binding compound or composition and melatonin together, preferably at normal bed time.

The present invention relates to a new use for compounds that inhibit phosphodiesterase 1 (PDE1), e.g., that inhibit PDE1-mediated suppression of the dopamine D1 receptor and/or progesterone signaling pathways, including, e.g., methods of treatment or prophylaxis for conditions which may be ameliorated by enhancing the progesterone signaling response, particularly female sexual dysfunction.

The present invention relates to therapeutic immunoconjugates comprising SN-38 attached to an anti-Trop-2 antibody or antigen-binding antibody fragment. In preferred embodiments, the antibody may be an hRS7 antibody. The methods and compostions are of use to treat Trop-2 expressing cancers in human patients, preferably in patients who are resistant to or relapsed from at least one prior anti-cancer therapy, more preferably in patients who are resistant to or relapsed from treatment with irinotecan. The immunoconjugate may be administered at a dosage of 3 mg/kg to 18 mg/kg, preferably 8 to 12 mg/kg, more preferably 8 to 10 mg/kg. When administered at specified dosages and schedules, the immunoconjugate can reduce solid tumors in size and reduce or eliminate metastases. Preferred tumors to treat with the subject immunoconjugates include triple-negative breast cancer, HER+, ER+, progesterone+ breast cancer, metastatic non-small-cell lung cancer, a metastatic small-cell lung cancer and metastatic pancreatic cancer.

The invention provides a method for detecting progesterone and testosterone in saliva through a high performance liquid chromatography-tandem mass spectrometry technique.The method comprises the steps that the progesterone and the testosterone in pretreated saliva are detected by adopting the high performance liquid chromatography-tandem mass spectrometry technique, the progesterone and the testosterone are separated from impurities through high performance liquid chromatography, quantification is performed through an internal standard method, an isotope of the progesterone is taken as an internal standard, a calibration curve is built by taking the concentration ratio of a standard product to the internal standard as an X axis and taking the peak area ratio of the standard product to the internal standard as a Y axis, and the content of the progesterone and the testosterone is calculated.The method is high in sensitivity and specificity, good in accuracy and simple in pretreatment process; the analysis time is short, analysis of the progesterone and the testosterone can be completed in 6.5 min, and the precision degree and the standard recovery rate meet the detection requirement.

Disclosed is a test device to detect pregnancy In a human female subject, the test device comprising: an assay means to measure the absolute or relative amount of hCG m a sample from the subject; an assay means to measure the absolute or relative amount of FSH in a sample from the subject; and m assay means to measure the absolute or relative amount of one or mere progesterone metabolites I>> a sample from the subject.

Embodiments of the invention comprise a test strip configured to detect one or more metabolites of progesterone in urine, and optionally further detect one or more additional metabolites or hormones in urine within the same test strip. Embodiments of the invention are methods of utilizing such a test strip in association with avoidance of pregnancy, detection of menopause, and in association with fertility planning purposes. Embodiments of the invention are associated with the incorporation of a test strip within a testing kit, optionally further comprising a digital reader.

The invention discloses application of cyanidin-3-O-glucoside in preparing medicine for preventing and/or treating male genital diseases caused by 1,3-dichloro-2-propanol. Research results show that the C3G has a significant inhibitory effect on R2C cell activity decline, cell morphological damage, increase in cell apoptosis rate and the like exposed by 1,3-DCP, the C3G, by promoting the expression of StAR, 3beta-HSD and like key protein, intervenes in R2C cell progesterone synthesis exposed by the 1,3-DCP and simultaneously the C3G, by reducing ROS (reactive oxygen species) inside the R2C cell exposed by the 1,3-DCP and further inhibiting MMP (mitochondrial membrane potential) and the like, intervenes in R2C cell apoptosis and progesterone expression function injury caused by the 1,3-DCP. The research achievement of the invention provides an important basis for human to prevent and treat male genital diseases caused by 1,3-dichloro-2-propanol and has a great research significance.

The invention provides a method for treatment of primary progesterone receptor-negative (PR−) endometrial cancer comprising administering (i) cridanimod or a salt or an ester thereof and (ii) a progesterone receptor (PR) agonist. The invention further provides a method for treatment of a primary estrogen receptor-negative (ER−) breast cancer, comprising administering (i) cridanimod or a salt or an ester thereof and (ii) a selective estrogen receptor modulator (SERM) or a selective estrogen receptor down-regulator (SERD). Also provided are compositions related to the above methods.

The invention discloses an analytical method of utilizing adherent cell-human ovarian granular cell tumor cell strain (KGN) to evaluate in-vitro biological activity of human follicle stimulating hormone. The method comprises the following steps: using the human follicle stimulating hormone to stimulate the human ovarian granular cell tumor cell, measuring the content of generated progesterone, so as to reflect the activity of the human follicle stimulating hormone. The analytical method of using the human ovarian granular cell tumor adherent cell to evaluate the in-vitro biological activity of the human follicle stimulating hormone, disclosed by the invention, is effective, stable and quick, and avoids the limitations of long time consumption, complicated operation and poor result repeatability in the animal in-vivo ovarian weight increment method; meanwhile, the progesterone content is determined by a commercial enzyme linked immunosorbent assay (ELISA) kit, so that the biological activity of the human follicle stimulating hormone can be reflected truly and more accurately.

The invention discloses a high-throughput screening method for progesterone response defect infertility human sperm samples. According to the invention, healthy reproductive men are used as normal control, a male patient with infertility caused by unknown reasons is used as a research object, the effect of progesterone among different human sperm samples on the concentration ([Ca<2+>]i) of free Ca<2+> in head cells is observed and screened at high throughput, human sperm infertility samples with progesterone response defects are efficiently and rapidly screened while the dosing time differenceis avoided, the influence of progesterone on the human sperm function and the molecular mechanism of progesterone are further explored, and meanwhile, the clinical significance of sperm membrane progesterone receptor function defects in evaluation of male infertility causes is expected to be illuminated.

The invention discloses a method for testing influence of midazolam on development of testicular interstitial cells cultured in vitro. Comprising the following steps: culturing rats, separating CD90 positive cells, culturing testicular mesenchymal stem cells (SLC), detecting the influence of midazolam on proliferation and differentiation, amplifying the SLCs and detecting the cell activity, carrying out DAPI dyeing and counting, analyzing cells by a flow cytometer, analyzing testosterone (T) and progesterone (P4), carrying out mRNA and protein expression detection through QPCR (Quantitative Polymerase Chain Reaction) and WB (White Brown) experiments, and determining significant differences and drawing a chart through SNK (Sodium Nitrogen Kinase) detection. The steps are simple, and the influence of midazolam medicine on proliferation and differentiation of the testicular mesenchymal stem cells can be effectively verified.

Disclosed herein are devices, systems, methods and kits for performing immunoassay tests to detect for at least progesterone or analytes of progesterone on a sample in association with diagnosing problems and issues associated with corpus luteum functionality. The immunoassay devices and methods may be used in conjunction with diagnostic reader systems and/or a base unit for obtaining a sensitive readout of the immunoassay results. The methods disclosed herein may also incorporate steps associated with evaluating the urine of a sample for the presence of an estrogen metabolite and/or luteinizing hormone.

The invention discloses a layered microneedle, a layered microneedle contraception system and a preparation method and application of the layered microneedle, the layered microneedle comprises a polystyrene (PS) layer and a polyvinylpyrrolidone (PVP) layer, a needle body of the layered microneedle contraception system comprises nanospheres LNG (at) PCL/F68 and free levonorgestrel (LNG), and the nanospheres LNG (at) PCL/F68 are prepared by mixing the levonorgestrel (LNG), polycaprolactone (PCL) and poloxamer 188 (F68). A certain amount of medicine can be continuously and stably released by adjusting the dosage of F68 or the input amount of medicine LNG, and the requirements of different crowds for contraception duration are met. Meanwhile, due to the removable design of the layered microneedle substrate, the discomfort caused by the fact that other percutaneous preparations such as dressings stay on the skin surface for a long time is avoided, and the embarrassment that a patient uses contraceptive products is avoided.

The subject matter of the instant invention is pertinent to the field of hormone therapy. More specifically, the subject matter of the instant invention concerns methods of treating estrogen-dependent conditions such as endometrial hyperplasia and endometrial cancer in a female undergoing estrogen and/or selective estrogen receptor modulator (SERM) therapy. The instant invention is also relevant to the suppression of endometrial proliferation. The instant invention is also relevant to the treatment of pain associated with endometriosis. The compositions for practicing the methods, comprising progesterone antagonists are also disclosed. Embodiments of the instant invention also disclose methods for identifying new selective progesterone receptor modulators for practicing disclosed methods of treatment.